In what the company called part of a "multistep commercialization strategy" for DX-88, Dyax Corp. licensed North American and European rights to the intravenous formulation of the compound for use in preventing blood loss during surgery to Cubist Pharmaceuticals Inc. in a potential $231.5 million deal. (BioWorld Today) Read More
